Clinical trial · Observational
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
RETROSPECTIVE CHART REVIEW STUDY OF FIRST LINE LORLATINIB IN LOCALLY ADVANCED/METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS IN CHINA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer ALK-positive | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lorlatinib | Drug | Lorlatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Lorlatinib in locally advanced/metastatic ALK-positive Non-Small Cell Lung Cancer Patients in China
- interventionNames
- Drug: Lorlatinib
Primary outcomes (21)
- measure
- Age at Start of Lorlatinib Treatment
- timeFrame
- At initiation of lorlatinib treatment between July 2022- October 2024
- description
- Number of percentages of patients by age
- measure
- Smoking status (if available) at Start of Lorlatinib Treatment
- timeFrame
- At initiation of lorlatinib treatment between July 2022- October 2024
- description
- Number of patients by smoking status
- measure
- Histology of patients at start of Lorlatinib treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Age ≥18 years 2. Diagnosed with a/mNSCLC 3. Confirmed testing for ALK-positive 4. Initiated first-line lorlatinib treatment during the patient selection period, prior therapy such as adjuvant or neoadjuvant treatment are allowed. 5. A minimum lookback period of at least 3 months to establish a baseline period and ensure first-line use of cohort entry drug 6. Have at least 6 months of follow-up data available (early death or progression will be included)
References
Publications (0)
Data not yet available